DUXAP8 and neoplasm: Ji et al. (2020) have also revealed that DUXAP8 is notably increased in non-small-cell lung cancer (NSCLC) tissues, and is associated with lymph node metastases and advanced tumor stages. Sun et al. (2017) analyzed tumor tissue and normal tissue from 78 pairs of patients, and found that DUXAP8 was notably increased in tumor tissues compared with normal tissues. Elevated DUXAP8 expression has been positively correlated with tumor size, lymph node metastasis, tumor stage, shorter survival time, and shorter progression-free survival time (Sun et al., 2017; Li L.M. et al., 2021).